Tilray Brands Stock (NASDAQ:TLRY)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.21

52W Range

$3.67 - $23.20

50D Avg

$4.45

200D Avg

$6.58

Market Cap

$462.98M

Avg Vol (3M)

$4.02M

Beta

1.92

Div Yield

-

TLRY Company Profile


Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

3,595

IPO Date

Jul 19, 2018

Website

TLRY Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMay 26May 25May 24
Wellness Business$65.89M$60.48M$55.31M
Cannabis Segment$352.31M$330.61M$370.69M
Beverage Alcohol Business$265.46M$253.18M$213.61M
Distribution Revenue$327.24M$271.23M$258.74M

Fiscal year ends in May 26 | Currency in USD

TLRY Financial Summary


May 26May 25May 24
Revenue$915.45M$1.13B$1.07B
Operating Income$-63.03M$-3.13B$-238.10M
Net Income$-105.16M$-3.00B$-333.80M
EBITDA$-63.03M$-2.92B$-99.25M
Basic EPS$-1.09$-33.80$-4.50
Diluted EPS$-1.09$-33.80$-4.50

Fiscal year ends in May 26 | Currency in USD

Latest Earnings Call Transcripts


Q4 26Jul 28, 26 | 4:30 PM
Q3 26Apr 01, 26 | 8:30 AM
Q2 26Jan 08, 26 | 3:45 PM

Peer Comparison


TickerCompany
NEOGNeogen Corporation
IMNMImmunome, Inc.
HROWHarrow Health, Inc.
ALVOAlvotech
EVOEvotec SE
AMPHAmphastar Pharmaceuticals, Inc.
MAZEMaze Therapeutics, Inc.
PAHCPhibro Animal Health Corporation
NTLAIntellia Therapeutics, Inc.
DVAXDynavax Technologies Corporation